Current Neuro-Oncology

Volume 23 Number 23
15 December 2021

Home > Publications > Current Neuro-Oncology > Volume 23, Year 2021 > Number 23, 15 December

Tinkle CL, Broniscer A, Chiang J, Campagne O, Huang J, Orr BA, Li X, Patay Z, Zhang J, Baker SJ, Merchant TE, Jain V, Onar-Thomas A, Stewart CF, Wetmore C, Gajjar A.
Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG.
Neurooncol Adv. 2021 Dec 1, 2021;3(1):vdab179
. doi: 10.1093/noajnl/vdab179. PMID: 34993482. Interventional study. ˍ

Hu JL, Omofoye OA, Rudnick JD, Kim S, Tighiouart M, Phuphanich S, Wang H, Mazer M, Ganaway T, Chu RM, Patil CG, Black KL, Shiao SL, Wang R, Yu JS.
A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma.
Clin Cancer Res. 2021 Dec 2, 2021;28(4):689-696
. doi: 10.1158/1078-0432.CCR-21-2867. PMID: 34862245. Interventional study. ˍ

Silva AHD, Constantinides M, Valetopoulou A, Sgardelis P, Mankad K, D'Arco F, Jankovic I, Thompson D.
Paediatric spinal cord low-grade gliomas-evaluation and management of post-surgical residual disease.
Childs Nerv Syst. 2021 Dec 2, 2021;38(3):577-586
. doi: 10.1007/s00381-021-05412-4. PMID: 34855000. Observational study˰ ˍ

Uchinomura S, Mitamura K, Norikane T, Yamamoto Y, Oishi A, Hatakeyama T, Miyake K, Nishiyama Y.
Distinguishing between primary central nervous system lymphoma and glioblastoma using [18F]fluoromisonidazole and [18F]FDG PET.
Nucl Med Commun. 2021 Dec 2, 2021;43(3):270-274
. doi: 10.1097/MNM.0000000000001510. PMID: 34864812. Observational study˰ ˍ

O'Rawe M, Wickremesekera AC, Pandey R, Young D, Sim D, FitzJohn T, Burgess C, Kaye AH, Tan ST.
Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial.
J Clin Neurosci. 2021 Dec 4, 2022;95:48-54
. doi: 10.1016/j.jocn.2021.11.023. PMID: 34929651. Interventional study. ˍ

Wang SQ, Yuan Q, Zhang GT, Qian HP, Liu ZD, Wang JW, Cai HQ, Wan JH.
Preoperative blood testing for glioblastoma, brain metastases, and primary central nervous system lymphoma differentiation.
Transl Cancer Res. 2021 Dec 7, 2022;11(1):63-71
. doi: 10.21037/tcr-21-1957. PMID: 35261885. Observational study. ˍ

Değerli E, Alkan G, Öztaş NŞ, Bedir Ş, Derin S, Demirci NS.
Bevacizumab-induced isolated oculomotor nerve palsy in glioblastoma multiforme.
J Oncol
Pharm Pract. 2021 Dec 8, 2021;28(3):746-749. doi: 10.1177/10781552211066888. PMID: 34878367. Case report˰ ˍ

Gu Q, Huang Y, Zhang H, Jiang B.
Case Report: Five Adult Cases of H3K27-Altered Diffuse Midline Glioma in the Spinal Cord.
Front Oncol. 2021 Dec 8, 2021;11:701113
. doi: 10.3389/fonc.2021.701113. PMID: 34956856. Case report. ˍ

Haubold J, Hosch R, Parmar V, Glas M, Guberina N, Catalano OA, Pierscianek D, Wrede K, Deuschl C, Forsting M, Nensa F, Flaschel N, Umutlu L.
Fully Automated MR Based Virtual Biopsy of Cerebral Gliomas.
Cancers (Basel). 2021 Dec 8, 2021;13(24):6186
. doi: 10.3390/cancers13246186. PMID: 34944806. Observational study. ˍ

Chato L, Latifi S.
Machine Learning and Radiomic Features to Predict Overall Survival Time for Glioblastoma Patients.
J Pers Med. 2021 Dec 9, 2021;11(12):1336
. doi: 10.3390/jpm11121336. PMID: 34945808. Observational study. ˍ

Porter AB, Liu H, Kohli S, Cerhan JL, Sloan J, McMurray RP, Le-Rademacher J, Loprinzi CL, Villano JL, Kizilbash SH, Mehta MP, Jaeckle KA, Brown PD.
Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma: A Phase 3 Randomized Clinical Trial.
JAMA Oncol. 2021 Dec 9, 2021;8(2):259-267
. doi: 10.1001/jamaoncol.2021.5948. PMID: 34882169. Interventional study. ˍ

Feng A, Yuan P, Huang T, Li L, Lyu J.
Distinguishing Tumor Recurrence From Radiation Necrosis in Treated Glioblastoma Using Multiparametric MRI.
Acad Radiol. 2021 Dec 9,
2022;29(9):1320-1331. doi: 10.1016/j.acra.2021.11.008. PMID: 34896001. Observational study˰ ˍ


Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco MR, Shai A, Wong CM, Rabbitt JE, Olin MR, Moertel CL, Nishioka Y, Salazar AM, Molinaro AM, Phillips JJ, Butowski NA, Clarke JL, Oberheim Bush NA, Hervey-Jumper SL, Theodosopoulos P, Chang SM, Berger MS, Okada H.
Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas.
J Clin Invest. 2021 Dec 9, 2021;132(3):e151239
. doi: 10.1172/JCI151239. PMID: 34882581. Interventional study. ˍ

Qiu X, Chen Y, Bao Z, Chen L, Jiang T.
Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.
Radiother Oncol. 2021 Dec 10, 2021;167:1-6
. doi: 10.1016/j.radonc.2021.12.009. PMID: 34902368. Interventional study. ˍ

Cebula H, Garnon J, Todeschi J, Noel G, Lhermitte B, Mallereau CH, Chibbaro S, Burckel H, Schott R, de Mathelin M, Gangi A, Proust F.
Interventional magnetic-resonance-guided cryotherapy combined with microsurgery for recurrent glioblastoma: An innovative treatment?
Neurochirurgie. 2021 Dec 11,
2022;68(3):267-272. doi: 10.1016/j.neuchi.2021.11.004. PMID: 34906554. Observational study˰ ˍ

Lucas JT, Tinkle CL, Huang J, Onar-Thomas A, Srinivasan S, Tumlin P, Becksfort J, Klimo P, Boop FA, Robinson GW, Orr BA, Harreld JH, Krasin MJ, Northcott PA, Ellison DW, Gajjar A, Merchant TE.
Revised clinical and molecular risk strata define the incidence and pattern of failure in Medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study.
Neuro Oncol. 2021 Dec 11,
2022;24(7):1166-1175. doi: 10.1093/neuonc/noab284. PMID: 34894262. Interventional study. ˍ

Skardelly M, Kaltenstadler M, Behling F, Mäurer I, Schittenhelm J, Bender B, Paulsen F, Hedderich J, Renovanz M, Gempt J, Barz M, Meyer B, Tabatabai G, Tatagiba MS.
A Continuous Correlation Between Residual Tumor Volume and Survival Recommends Maximal Safe Resection in Glioblastoma Patients: A Nomogram for Clinical Decision Making and Reference for Non-Randomized Trials.
Front Oncol. 2021 Dec 13, 2021;11:748691
. doi: 10.3389/fonc.2021.748691. PMID: 34966669. Observational study. ˍ

Teske N, Karschnia P, Weller J, Siller S, Dorostkar MM, Herms J, von Baumgarten L, Tonn JC, Thon N.
Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
J Neurooncol. 2021 Dec 13, 2022;156(2):317-327
. doi: 10.1007/s11060-021-03912-6. PMID: 34902093. Observational study. ˍ


Lin Y, Chen B.
Case report: tumor-treating fields prolongs IDH-mutant anaplastic astrocytoma progression-free survival and pathological evolution to glioblastoma.
Ann Transl Med. 2021 Dec 14, 2021;9(24):1804
. doi: 10.21037/atm-21-4760. PMID: 35071498. Case report. ˍ

Chen J, Zhao Y, Hou X, Gao X, Shi Q, Li S, Huang H.
Combined carboplatin and etoposide chemotherapy for patients with recurrent glioma.
Ann Palliat Med. 2021
Dec 15, 2021;10(12):12650-12656. doi: 10.21037/apm-21-3382. PMID: 35016422. Observational study. ˍ

Lei J, Zhou Z.
Efficacy and safety of bevacizumab combined with temozolomide in the treatment of recurrent malignant gliomas and its influence on serum tumor markers.
Am J Transl Res. 2021 Dec 15, 2021;13(12):13886-13893
. PMCID: PMC8748084. PMID: 35035729. Observational study. ˍ

Wei KC, Hsu PW, Tsai HC, Lin YJ, Chen KT, Toh CH, Huang HL, Jung SM, Tseng CK, Ke YX.
Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study.
Sci Rep. 2021 Dec 15, 2021;11(1):24067
. doi: 10.1038/s41598-021-02527-1. PMID: 34911992. Interventional study. ˍ